Science Days are an important milestone in many large, complex litigations. Our Firm has received Byetta lawsuit inquiries from a number of individuals, and we are pleased to see the federal litigation moving forward.
New York., NY (PRWEB) December 03, 2013
Byetta lawsuits (http://www.byettalawsuit2013.com/ ), as well as product liability claims involving other incretin mimetic diabetes drugs, continue to move forward in a multidistrict litigation now underway in U.S. District Court, Southern District of California. According to an Order issued on November 25, 2013, the Court has scheduled Science Days in the proceeding for February 5 and 6, 2014. The Science Days will allow the parties, in a non-adversarial manner, to apprise the Court of a number of issues relevant to Byetta lawsuits and other claims pending in the proceeding, including: the nature of Type 2 Diabetes; the role of the medications in treating diabetics; data regarding the effects of the incretin mimetics on the pancreas; and information concerning pancreatic cancer, including associated morbidity and mortality rates. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)
“Science Days are an important milestone in many large, complex litigations. Our Firm has received Byetta lawsuit inquiries from a number of individuals, and we are pleased to see the federal litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free case evaluations to patients who took Byetta and were diagnosed with pancreatic cancer, thyroid cancer or pancreatitis.
Byetta and Pancreatic Cancer
According to court documents, more than 150 lawsuits have been filed in the federal incretin mimetics litigation, many of which allege a link between the use of Byetta and pancreatic cancer. The makers of the drugs are accused of failing to warn doctors and patients about the serious risks associated with this class of diabetes medications.
Court records indicate that Byetta lawsuit filings have been mounting since March 2013, when the U.S. Food & Drug Administration (FDA) announced a review of incretin mimetics, after a small study indicated they could cause potentially pre-cancerous changes in the cells of the pancreas. The FDA has so far been unable to reach a conclusion in this matter, but its review continues.
One month after the FDA announced its incretin mimetics review, the Institute for Safe Medicine Practices revealed that the FDA had received 263 reports of pancreatitis, 71 cases of pancreatic cancer, and 14 incidents of thyroid cancer among patients taking Byetta in a single 12-month period. The same review also found that compared to other classes of diabetes medications, incretin mimetics were far more likely to be associated with pancreatic cancer.*
Patients suffering from pancreatic cancer, as well as thyroid cancer and pancreatitis, allegedly associated with Byetta may be entitled to compensation for any damages related to their injuries. To learn more about the possible association between Byetta and pancreatic cancer, please visit Bernstein Liebhard LLP’s website. For a free Byetta lawsuit review, please call 800-511-5092.
*ismp.org/quarterwatch/pdfs/2012Q3.pdf, ISMP, April 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com